

MAELOR PLC  
10 April 2007

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN  
ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR  
COMPANIES ('AIM RULES')

COMPANY NAME: Maelor plc

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS  
(INCLUDING POSTCODES) :

Office Village,  
Chester Business Park,  
Chester CH4 9QZ

COUNTRY OF INCORPORATION: United Kingdom

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:  
[www.maelor.plc.uk](http://www.maelor.plc.uk)

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN  
INVESTING COMPANY, DETAILS OF ITS  
INVESTING STRATEGY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-  
OVER UNDER RULE 14, THIS SHOULD BE  
STATED:

Company business

Maelor is a specialist pharmaceuticals and medical devices company, focused in the critical care market. The Company has expertise in developing and commercialising both pharmaceuticals and medical devices. The new management team is committed to delivering the vision of establishing a significant business in specialist hospital medicine, initially focused in the critical care sector. This vision will be realised through aggressive acquisition, development and organic growth of late stage and launched products, to rapidly drive turnover and profit.

Main Country of Operation

United Kingdom

Admission is sought in connection with a reverse take-over under Rule 14

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER  
OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to  
which it seeks admission and the number and type to be held as treasury shares):

Re-Admission Existing Ordinary Shares of 10p each	34,280,833
New Ordinary shares of 10p each (at an issue price of 10p)	90,000,000
Total number of Ordinary shares	124,280,833

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET  
CAPITALISATION ON ADMISSION:

fundraising £8 million, £12.4 million market capitalisation

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

10.5% (Directors and Vendors)

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES  
(OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

not applicable / none

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

John Gregory / Non-Executive Director

Tim Wright / Chief Executive Officer

Geoff McMillan / Non-Executive Chairman

Peter Murray / Non-Executive Director

Ann Hardy / Operations Director

Nigel Goldsmith / Finance Director

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Significant Shareholders before Admission

	As at date of this document	
	No. of Ordinary Shares	% of issued share capital
Chase Nominees Limited	6,124,812	17.9%
Barclayshare Nominees Limited	2,839,876	8.3%
TD Waterhouse Nominees (Europe)	2,518,495	7.3%
Capita Trust Company Limited	1,404,296	4.1%
HSDL Nominees Limited	1,061,877	3.1%

Significant Shareholders after Admission

	As at date of this document		Immediately following the document		Acquisition, the Placing and Admission	
	No. of Ordinary Shares	% of issued share capital	No. of ordinary shares	% of issued share capital	No. of ordinary shares	% of issued share capital
State Street Nominees Limited	-	-	11,200,000	9.0%	11,200,000	9.0%
MD Barnard & Co Limited	-	-	10,000,000	8.0%	10,000,000	8.0%
HSBC Nominees Limited	-	-	6,500,000	5.2%	6,500,000	5.2%
Chase Nominees Limited <sup>1</sup>	6,123,812	17.9%	6,123,812	4.9%	6,123,812	4.9%
Brewin Nominees Limited	-	-	6,000,000	4.8%	6,000,000	4.8%
JP Morgan Chase Nominees Limited <sup>1</sup>	-	-	5,000,000	4.0%	5,000,000	4.0%
Pershing Keen Nominees Limited	-	-	4,900,000	3.9%	4,900,000	3.9%
Heartwood Nominees Limited <sup>2</sup>	-	-	3,200,000	2.6%	3,200,000	2.6%
Barclayshare Nominees Limited	2,839,876	8.3%	2,839,876	2.3%	2,839,876	2.3%
TD Waterhouse Nominees (Europe) Limited	2,518,495	7.3%	2,518,495	2.0%	2,518,495	2.0%
Capita Trust Company Limited <sup>2</sup>	1,404,296	4.1%	1,404,296	1.1%	1,404,296	1.1%
HSDL Nominees Limited	1,061,877	3.1%	1,061,877	0.9%	1,061,877	0.9%

1 held as nominee for Bluehone Investors LLP

2 held as nominee for Close Investments Limited

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2,  
PARAGRAPH (H) OF THE AIM RULES:

none

- (i) ANTICIPATED ACCOUNTING REFERENCE DATE 31 March
- (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED: 30 September 2006
- (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:30 September 2007, 30 December 2007, 30 September 2008

EXPECTED ADMISSION DATE:

First Admission on 8 May 2007 in relation to 70,005,833 Existing Ordinary and New VCT/EIS Shares

Second Admission on 9 May 2007 in relation to 44,275,000 Protected VCT and Non-VCT Shares

Third Admission on 10 May 2007 in relation to 10,000,000 Consideration Shares

NAME AND ADDRESS OF NOMINATED ADVISER:

Noble & Company Limited

120 Old Broad Street

London EC2N 1AR

NAME AND ADDRESS OF BROKER:

Noble & Company Limited

120 Old Broad Street

London EC2N 1AR

Lewis Charles Securities Ltd

4 - 7 Chiswell Street

London EC1Y 4UP

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

Noble & Company Limited

120 Old Broad Street

London

EC2N 1AR

DATE OF NOTIFICATION: 10 April 2007

NEW/ UPDATE: NEW

END